Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic prioritisation
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (9)
Type
(
1 selected
)
Type
Guidance (312)
Quality standard (29)
Guidance programme
Guidance programme
Health technology evaluations (4)
HealthTech guidance (2)
Highly specialised technologies guidance (1)
Interventional procedures guidance (6)
Medical technologies guidance (2)
Technology appraisal guidance (297)
Apply filters
Showing 26 to 50 of 312
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]
Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]
Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Technology appraisal guidance
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]
Technology appraisal guidance
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]
Technology appraisal guidance
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]
Technology appraisal guidance
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]
Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Technology appraisal guidance
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]
Technology appraisal guidance
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]
Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Technology appraisal guidance
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]
Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Technology appraisal guidance
Rivaroxaban for treating chronic heart failure [ID1462]
Technology appraisal guidance
Dulaglutide for treating type 2 diabetes [ID1451]
Technology appraisal guidance
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Technology appraisal guidance
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]
Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture [ID6276]
Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]
Technology appraisal guidance
CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210]
Technology appraisal guidance
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]
Technology appraisal guidance
Ondansetron for treating alcohol-use disorder [ID6341]
Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]
Technology appraisal guidance
Previous page
1
Current page
2
3
4
…
13
Page
2
of
13
Next page
Results per page
10
25
50
All
Back to top